ANI Pharmaceuticals to Present Research at ASN Kidney Week 2024
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) is set to unveil exciting new pre-clinical data regarding its membranous nephropathy (MN) research. The presentations will take place during two poster sessions at the esteemed American Society of Nephrology (ASN) Kidney Week 2024.
The Significance of the ASN Kidney Week
This event, one of the largest in the nephrology community, gathers experts and professionals to discuss advancements in kidney health. It serves as a platform for networking and sharing breakthrough research. At this year's conference, ANI Pharmaceuticals aims to illuminate the potential mechanistic roles of melanocortin receptors in nephrotic syndrome.
Exciting Findings from ANI Pharmaceuticals
Mary Pao, MD, PhD, the Chief Medical Officer at ANI, expressed enthusiasm about the data being presented: "These findings shed light on the potential role of melanocortin receptors in the underlying disease pathologies within nephrotic syndrome. We are committed to advancing paired research tools and models for studying membranous nephropathy."
Details of the Poster Presentations
ANI Pharmaceuticals has lined up two pivotal poster presentations:
1. THSD7A-Associated Membranous Nephropathy
This poster, titled "THSD7A-Associated Membranous Nephropathy Involves Both Complement-Mediated and Autonomous Podocyte Injury," will focus on the mechanisms that impact podocyte health. It will be featured on Friday from 10 AM to 12 PM, with Jing Liu as the lead author.
2. Podocyte-Specific Signaling Activation
The second poster, entitled "Activation of Podocyte-Specific MC5R Signaling by Melanocortin Therapy Protects Against THSD7A-Associated Membranous Nephropathy," is scheduled for Saturday during the same time. This work also showcases Jing Liu's significant contributions to the study.
Access to Abstracts and Further Information
For those interested in diving deeper into the research presented, the abstracts will be available online shortly after the conference. ANI Pharmaceuticals' participation will undoubtedly underscore its focus on developing innovative therapeutic strategies addressing rare diseases.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc. is a dedicated biopharmaceutical company committed to improving patient outcomes through the development and marketing of high-quality branded and generic prescription pharmaceutical products. With a keen focus on addressing unmet medical needs, ANI is evolving its Rare Disease segment, bolstering its Generics operation via advanced research and development, and ensuring that it continues to lead in established brands.
The company leverages a robust U.S. manufacturing base, strengthening its commitment to delivering the highest quality products. More information about ANI Pharmaceuticals can be found online, providing insight into their commitment to sustainable growth.
Frequently Asked Questions
What is membranous nephropathy?
Membranous nephropathy is a kidney disorder characterized by inflammation and damage to the membranes of the glomeruli, affecting kidney function.
When will ANI Pharmaceuticals present its findings?
ANI Pharmaceuticals will present its findings at ASN Kidney Week 2024, taking place from October 23-27.
What research will ANI Pharmaceuticals showcase?
ANI will showcase two posters focusing on new data regarding melanocortin receptors and their role in podocyte injury related to nephrotic syndrome.
Who is leading the research presentations?
Jing Liu will be leading the presentations for both poster sessions at the event.
Where can I find more information about ANI Pharmaceuticals?
Further information can be found on the ANI Pharmaceuticals website, which details their diverse portfolio and commitment to patients.
